Puma Biotechnology, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2011. The filing contains separate financial statements for the pre-merger public shell, Innovative Acquisitions Corp., and privately held Puma Biotechnology. It does not present combined post-merger financial results for the period.
Business context and transaction
Before the merger, the public shell had no active operating business. Private Puma was a development-stage biopharmaceutical company seeking to in-license and develop cancer drug candidates, with neratinib as its primary focus. On October 4, 2011, Puma completed a reverse merger with the shell; Puma was the accounting acquirer, and the company adopted Puma’s business and name. Puma’s former stockholders received 18,666,733 shares, and the shell’s former holders’ 3,000,000 shares were redeemed for $40,000, plus transaction-related professional costs.
Financial results and liquidity
| Private Puma (USD) | Three months ended Sep. 30, 2011 | Nine months ended Sep. 30, 2011 | Comparable 2010 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $333,934 | $372,140 | $6,631 |
| Other expense | $13,500 | $13,500 | $0 |
| Net loss | $347,434 | $385,640 | $6,631 |
| Basic and diluted loss per share | $0.087 | $0.096 | $0.002 |
Private Puma’s operating expenses were primarily legal and travel costs related to the Pfizer license agreement and reverse merger. The filing reports no revenue, so operating or net margins are not meaningful.
- Private Puma at September 30: Cash was $25,467; total assets were $38,391. Current liabilities totaled $362,048, comprising $212,048 accounts payable and a $150,000 stockholder convertible note. Stockholders’ deficit was $323,657.
- Cash flow: Nine-month operating cash use was $183,153; financing provided $211,983, including the $150,000 stockholder note and $61,983 in capital contributions. Ending cash was $25,467.
- Public shell at September 30: No assets or liabilities and no revenue; nine-month net loss was $15,157. Its cash balance was $462 at December 31, 2010 and zero at September 30, 2011.
After quarter-end, Puma’s October 4 private placement sold 14,666,733 shares at $3.75 per share for approximately $55 million gross, before commissions and expenses. The filing reports placement-agent fees of $2,338,215 and a $75,000 expense reimbursement. The $55 million financing is a subsequent event, not September 30 cash.
Outlook, risks, and unusual items
- Management planned development of three drug candidates, principally neratinib for breast cancer. It estimated spending from the remaining months of 2011 through 2012 of approximately $27 million on clinical and research and development, $6.3 million on general and administrative costs, $0.5 million on rent, and $250,000 on capital expenditures. It also anticipated hiring up to 44 research and development employees and five general and administrative employees.
- Based on resources as of November 14, management believed the company had sufficient capital to fund operations through December 2012, but said additional financing would be needed thereafter and that no further financing was committed. Management cautioned that financing might not be available on acceptable terms, or at all.
- The neratinib license became effective October 4, subject to financing and net-worth conditions. It provides for milestone payments of up to $187.5 million and royalties if the drug is commercialized.
- The $150,000 stockholder note was non-interest-bearing and convertible; it was converted into 40,000 shares on October 6. The filing also describes registration-rights provisions that may require liquidated damages if specified deadlines are missed.
- Management identified financing, clinical and regulatory progress, product development, customer relationships, and intellectual-property protection among factors that could affect results. No material pending legal proceedings were reported. Management concluded disclosure controls were effective as of September 30.
Investor facts to verify
- Reconcile the post-merger share count, including the 18,666,733 merger shares, the 40,000 note-conversion shares, and the reported 18,706,733 shares outstanding as of November 7.
- Confirm the private placement’s net proceeds after commissions, expenses, and other transaction costs, and the resulting cash runway.
- Review the neratinib license’s conditions, milestone triggers, royalty terms, and development obligations.
- Assess the planned clinical and R&D spending against the company’s cash needs and its stated reliance on future financing.
- Review the full risk factors and transaction documents referenced in the filing, including registration deadlines, potential liquidated damages, and dilution provisions.